Hyperthermic MMC—A Systematic Review

Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27(3):319–24.CrossRefGoogle Scholar

Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192(3):708–13.CrossRefGoogle Scholar

Arends TJ, Falke J, Lammers RJ, Somford DM, Hendriks JC, de Weijert MC, Arentsen HC, van der Heijden AG, Oosterwijk E, Alfred Witjes J. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol. 2015;33(10):1411–7.CrossRefGoogle Scholar

Ba M, Cui S, Wang B, Long H, Yan Z, Wang S, Wu Y, Gong Y. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncol Rep. 2017;37(5):2761–70.CrossRefGoogle Scholar

Bahouth Z, Halachmi S, Moskovitz B, Nativ O. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2016;16(2):189–98.CrossRefGoogle Scholar

Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, Servadio C, Caldarera E. Pavone-Macaluso M Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable NMI bladder tumors. J Urol. 1998;159(3):783–7.CrossRefGoogle Scholar

Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–8.CrossRefGoogle Scholar

Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk NMI bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–82.CrossRefGoogle Scholar

D’Souza N, Verma A. Holmium laser transurethral resection of bladder tumor: our experience. Urol Ann. 2016;8(4):439.CrossRefGoogle Scholar

Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, Divrik RT, Zorlu F. Results of Intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pac J Cancer Prev. 2015;16(8):3241–5.CrossRefGoogle Scholar

Geijsen ED, de Reijke TM, Koning CC, Zum Vörde Sive Vörding PJ, de la Rosette JJ, Rasch CR, van Os RM, Crezee J. Combining mitomycin C and regional 70 MHz hyperthermia in patients with nonmuscle invasive bladder cancer: a Pilot study. J Urol. 2015;194(5):1202–8.Google Scholar

Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade NMI bladder cancer. Urology. 2004;63(3):466–71.CrossRefGoogle Scholar

Gözen AS, Umari P, Scheitlin W, Su FE, Akin Y, Rassweiler J. Effectivity of intravesical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer. Arch Ital Urol Androl. 2017;89(2):102–5.CrossRefGoogle Scholar

Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, Sandri SD, Nativ O, Colombo R. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011;29(3):259–64.CrossRefGoogle Scholar

Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2014;30(3):171–5.CrossRefGoogle Scholar

Kiss B, Schneider S, Thalmann GN, Roth B. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? Int J Urol. 2015;22(2):158–62.CrossRefGoogle Scholar

León-Mata J, Domínguez JL, Redorta JP, Sousa González D, Alvarez Casal M, Sousa Escandón A, Piñeiro Vázquez E. Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. Arch Esp Urol. 2018;71(4):426–37.Google Scholar

Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10(Suppl. 1):6–20.CrossRefGoogle Scholar

Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in NMI transitional cell carcinoma patients. Cancer Chemother Pharmacol. 2014;73(3):503–9.CrossRefGoogle Scholar

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ. 2009;339(7716):332–6.CrossRefGoogle Scholar

Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, Nativ O. Thermo-chemotherapy for intermediate or high-risk recurrent NMI bladder cancer patients. Ann Oncol. 2005;16(4):585–9.CrossRefGoogle Scholar

Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol. 2009;182(4):1313–7.CrossRefGoogle Scholar

Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for NMI bladder tumors. A preliminary clinical study. Eur Urol. 1991;20(3):204–10.CrossRefGoogle Scholar

Sooriakumaran P, Chiocchia V, Dutton S, Pai A, Ayres BE, Le Roux P, Swinn M, Bailey M, Perry MJ, Issa R. Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients. Urol Int. 2016;96(1):83–90.CrossRefGoogle Scholar

Sousa A, Piñeiro I, Rodríguez S, Aparici V, Monserrat V, Neira P, Carro E, Murias C, Uribarri C. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):374–80.CrossRefGoogle Scholar

van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351–62.Google Scholar

Volpe A, Racioppi M, Bongiovanni L, D’Agostino D, Totaro A, D’Addessi A, Marangi F, Palermo G, Pinto F, Sacco E, Bassi PF. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy? Urol Int. 2012;89(3):311–8.CrossRefGoogle Scholar